Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

6.370 +0.110 (+1.76%)
Delayed Quote Updated: 11:08 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences (NASDAQ:DTIL) Passes Minervini Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
News headline image
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
From Precision BioSciences, Inc.
Via Business Wire
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.